✦ LIBER ✦

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

✍ Scribed by José Valdez Madruga; Daniel Berger; Marilyn McMurchie; Fredy Suter; Denes Banhegyi; Kiat Ruxrungtham; Dorece Norris; Eric Lefebvre; Marie-Pierre de Béthune; Frank Tomaka; Martine De Pauw; Tony Vangeneugden; Sabrina Spinosa-Guzman

Book ID: 117301431
Publisher: The Lancet
Year: 2007
Tongue: English
Weight: 193 KB
Volume: 370
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(07)61049-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of darunavir-ritonav

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

✍ Bonaventura Clotet; Nicholas Bellos; Jean-Michel Molina; David Cooper; Jean-Chri 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 180 KB

IN2 Comparative Efficacy at 48 Weeks of

IN2 Comparative Efficacy at 48 Weeks of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Treatment Naive Hiv-1 Patients: A Matching Adjusted Indirect Comparison of Randomized Trials

✍ J. Xie; T. Juday; E. Swallow; X. Du; J. Uy; T. Hebden; J. Signorovitch 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Efficacy and safety of TMC125 (etravirin

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

✍ José Valdez Madruga; Pedro Cahn; Beatriz Grinsztejn; Richard Haubrich; Jacob Lal 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 193 KB

Efficacy and safety of TMC125 (etravirin

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

✍ Adriano Lazzarin; Thomas Campbell; Bonaventura Clotet; Margaret Johnson; Christi 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 193 KB

Safety and efficacy of the HIV-1 integra

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

✍ Beatriz Grinsztejn; Bach-Yen Nguyen; Christine Katlama; Jose M Gatell; Adriano L 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 179 KB

Efficacy and safety of once daily elvite

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

✍ Jean-Michel Molina; Anthony LaMarca; Jaime Andrade-Villanueva; Bonaventura Clote 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 209 KB